

Financial Report

x ...


o

+

x

o

.....



The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients.

We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options.

Contents

4 **Financial Review**

17 **Unaudited Interim
Consolidated Financial Statements**



Contents 

Financial Review

Unaudited Interim
Consolidated
Financial Statements

Financial Review

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Idorsia measures and reports its non-GAAP operating performance, which management believes more accurately reflects the underlying business performance. The Group believes that these non-GAAP financial measurements provide useful supplementary information for investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.

Rounding differences may occur
nm = not meaningful

Idorsia's key numbers

Profit and loss

(in CHF millions, except EPS)	US GAAP		Non-GAAP		US GAAP		Non-GAAP	
	2024	2023	2024	2023	2024	2023	2024	2023
Net revenue								
Product sales	49	54	49	54	25	10	25	10
Contract revenue – royalties	1	-	1	-	1	-	1	-
Contract revenue – milestones	3	73	3	73	1	69	1	69
Contract revenue – others	-	4	-	4	-	1	-	1
Operating expenses								
Cost of sales	(16)	(7)	(16)	(7)	(12)	(1)	(12)	(1)
Research and development	(111)	(235)	(95)	(212)	(40)	(63)	(34)	(59)
Selling, general and administrative	(209)	(318)	(194)	(299)	(66)	(69)	(60)	(64)
Net results								
Operating income (loss)	(154)	(144)	(248)	(386)	(90)	231	(78)	(44)
Net income (loss)	(180)	(181)	(258)	(420)	(101)	224	(75)	(51)
Basic EPS	(1.00)	(1.02)	(1.43)	(2.36)	(0.55)	1.26	(0.41)	(0.29)
Diluted EPS	(1.00)	(1.02)	(1.43)	(2.36)	(0.55)	0.96	(0.41)	(0.29)

Cash flow

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Cash flow				
Operating cash flow	(51)	(200)	(144)	243
Proceeds/ (repayments) of borrowings, net	-	-	-	(30)
Capital expenditure	(2)	(8)	(1)	(2)

Shares

(in millions)	Sep 30, 2024	Jun 30, 2024	Dec 31, 2023
---------------	--------------	--------------	--------------

Share count

Issued common shares	189.3	189.1	188.5
Equity derivatives	81.5	54.0	54.0
Equity instruments	18.1	17.0	14.6
Total potential issued shares	288.9	260.1	257.2

Liquidity and indebtedness

(in CHF millions)	Sep 30, 2024	Jun 30, 2024	Dec 31, 2023
Liquidity			
Cash and cash equivalents	92	237	145
Total liquidity	92	237	145
Indebtedness			
Convertible loan	335	335	335
Convertible bonds	797	797	796
Other financial debt	162	162	162
Total indebtedness	1,294	1,294	1,293

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Transaction with Nxera (formerly Sosei Heptares)

On July 20, 2023 Idorsia sold its Asia Pacific (ex-China) operations for a total consideration of CHF 400 m that led to a one-off profit of CHF 366 m of which CHF 68 m were recorded as contract revenue, CHF 305 m were recorded as gains on sale of disposal group and CHF 7 m were recorded as impairment charge of intangible assets. This transaction is referred hereafter as “the Nxera Deal”.

In addition to the US GAAP and Non-GAAP measures presented above, the company has prepared proforma figures corresponding to the scope of operations that the company currently operates excluding the APAC operations in 2023 until the closing of the Nxera Deal and the one-off impact of such transaction, as shown in the table below.

Operational performance as reported

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Revenue				
Product sales	49	54	25	10
Contract revenue - royalties	1	-	1	-
Contract revenue - milestones	3	73	1	69
Contract revenue - others	-	4	-	1
US GAAP revenue	53	131	26	80
Operating expenses				
Cost of sales	(16)	(7)	(12)	(1)
Research	(47)	(74)	(16)	(20)
Development	(48)	(138)	(18)	(39)
Selling	(136)	(246)	(42)	(56)
General and administrative	(58)	(53)	(18)	(7)
Non-GAAP operating expenses	(305)	(517)	(106)	(124)
Other income	5	-	2	-
Non-GAAP operating loss	(248)	(386)	(78)	(44)
Depreciation and amortization	(14)	(15)	(6)	(7)
Share-based compensation	(17)	(27)	(6)	(2)
Restructuring charges	(1)	(11)	-	(11)
Effect of the Viatris Deal	125	295	-	295
Other operating expenses	94	242	(12)	275
US GAAP operating loss	(154)	(144)	(90)	231

Operational performance proforma

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Revenue				
Product sales	49	20	25	8
Contract revenue - royalties	1	-	1	-
Contract revenue - milestones	3	5	1	1
Contract revenue - others	-	4	-	1
US GAAP revenue	53	29	26	11
Operating expenses				
Cost of sales	(16)	(4)	(12)	(1)
Research	(47)	(74)	(16)	(20)
Development	(48)	(130)	(18)	(38)
Selling	(136)	(228)	(42)	(54)
General and administrative	(58)	(49)	(18)	(7)
Non-GAAP operating expenses	(305)	(486)	(106)	(122)
Other income	3	-	1	-
Non-GAAP operating loss	(249)	(455)	(78)	(111)
Depreciation and amortization	(14)	(14)	(6)	(7)
Share-based compensation	(17)	(26)	(6)	(2)
Restructuring charges	(1)	(11)	-	(11)
Effect of the Viatris Deal	125	-	-	-
Other operating expenses	94	(52)	(12)	(20)
US GAAP operating loss	(155)	(509)	(90)	(132)

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Nine months and Q3 US GAAP and Non-GAAP numbers as reported below include the impact of the Nxera Deal described above.

Revenue

Revenue

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Revenue				
Product sales	49	54	25	10
Contract revenue - royalties	1	-	1	-
Contract revenue - milestones	3	73	1	69
Contract revenue - others	-	4	-	1
US GAAP revenue	53	131	26	80

Product sales comprised of:

- QUVIVIQ™ (daridorexant) with CHF 39.4 m net sales in the US, Germany, France, Switzerland, Italy, UK, Spain, Canada and Austria. US net sales do not fully reflect the volumes of the products dispensed due to coupon and co-pay programs.
- Sales to our partners for the Asia-Pacific-Region with CHF 9.2 m

Contract revenue from milestones consisted of the license of ACT-1002-4391 granted to Owkin.

Operating expenses

Operating expenses

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Operating expenses				
Cost of sales	16	7	12	1
Research	47	74	16	20
Development	48	138	18	39
Selling	136	246	42	56
General and administrative	58	53	18	7
Non-GAAP operating expenses	305	517	106	124
Depreciation and amortization	14	15	6	7
Share-based compensation	17	27	6	2
Restructuring charges	1	11	-	11
Effect of the Viatris Deal	(125)	(295)	-	(295)
Other operating expenses	(94)	(242)	12	(275)
US GAAP operating expenses	211	275	118	(150)

US GAAP operating expenses of CHF 211 m comprised of Non-GAAP operating expenses (CHF 305 m), depreciation and amortization (CHF 14 m) and share-based compensation (CHF 17 m). It also includes one-offs with restructuring charges (CHF 1 m) and the impact of the Viatris Deal (CHF 125 m net gain offsetting the operating expenses).

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Cost of sales

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Cost of sales				
Cost of goods sold	16	4	12	1
Royalty paid	-	3	-	0
US GAAP cost of sales	16	7	12	1

Cost of sales of CHF 16 m comprised the cost of goods sold (CHF 16 m).

Research and development (“R&D”) expenses

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
R&D expenses				
Research	47	74	16	20
Development	48	138	18	39
Non-GAAP R&D expenses	95	212	34	59
Depreciation and amortization	9	11	4	4
Share-based compensation	6	12	3	(0)
US GAAP R&D expenses	111	235	40	63

Non-GAAP research expenses of CHF 47 m, comprised of biology (CHF 14 m), chemistry (CHF 14 m), preclinical activities (CHF 18 m) and other activities (CHF 1 m).

Non-GAAP development expenses of CHF 48 m include a release of CHF 58 m to neutralize the costs incurred for selatogrel and cenerimod in connection with the Viatris Deal. Non-GAAP development expenses mainly comprised of CHF 29 m for clinical activities (including CHF 6 m study costs, mainly driven by late stage studies for daridorexant and lucerastat) and CHF 19 m for chemical and pharmaceutical development activities (including CHF 5 m for drug substance and drug product).

Selling, general and administrative (“SG&A”) expenses

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
SG&A expenses				
Selling	136	246	42	56
General and administrative	58	53	18	7
Non-GAAP SG&A expenses	194	299	60	64
Depreciation and amortization	4	4	2	3
Share-based compensation	10	15	4	2
US GAAP SG&A expenses	209	318	66	69

Non-GAAP SG&A expenses of CHF 194 m, comprised of commercial activities (CHF 136 m), information systems (CHF 21 m) and other support functions (CHF 37 m).

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Operating results

Non-GAAP and US GAAP operating results

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Operating results				
Revenues	53	131	26	80
Operating expenses	(305)	(517)	(106)	(124)
Other income	5	0	2	0
Non-GAAP operating income (loss)	(248)	(386)	(78)	(44)
Operating results				
Revenues	53	131	26	80
Operating expenses	(211)	(275)	(118)	150
Other income	5	0	2	0
US GAAP operating income (loss)	(154)	(144)	(90)	231

US GAAP operating loss of CHF 154 m comprised of Non-GAAP operating loss (CHF 248 m), depreciation and amortization (CHF 14 m), share-based compensation (CHF 17 m), a net gain from asset disposals deriving from the Viatris Deal (CHF 125 m), and restructuring charges (CHF 1 m).

Financial results

Financial results

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Financial results				
Interest income (expense), net	(14)	(15)	(5)	(5)
Other financial income (expense), net	6	(14)	8	(0)
Non-GAAP financial income (expense)	(8)	(29)	3	(5)
Accretion expense	(1)	(1)	(0)	(0)
Gain (loss) on securities	(2)	(4)	1	(0)
Other financial income (expense), net	(14)	-	(14)	-
US GAAP financial income (expense)	(25)	(34)	(11)	(5)

US GAAP financial expense of CHF 25 m mainly comprised of Non-GAAP financial expense (CHF 8 m), a consent fee paid in shares to the bondholders resulting from amended terms of the 2024 convertible bonds (CHF 14 m) and losses on marketable securities (CHF 2 m).

Non-GAAP financial expense of CHF 8 m mainly included interest expenses on the convertible bonds (CHF 11 m) and interest expense resulting from the sale and lease back transaction (CHF 5 m), partially offset by gains from exchange rate differences (CHF 8 m).

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Income tax

Income tax

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Income tax				
Income tax benefit (expense)	(1)	(5)	(1)	(2)
Non-GAAP tax benefit (expense)	(1)	(5)	(1)	(2)
Other tax benefit (expense)	1	2	0	1
US GAAP income tax benefit (expense)	(1)	(3)	(0)	(1)

US GAAP income tax expense of CHF 1 m mainly included the Non-GAAP tax expense of foreign affiliates (CHF 1 m).

Both US- and Non-GAAP income tax expense included an increase of the valuation allowance of CHF 21 m that related to deferred tax assets arising from operating losses which can be carried forward for 7 years.

Net results, EPS and shares

Net results

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Non-GAAP operating income (loss)	(248)	(386)	(78)	(44)
Financial income (expense)	(8)	(29)	3	(5)
Income tax benefit (expense)	(1)	(5)	(0)	(2)
Non-GAAP net income (loss)	(258)	(420)	(75)	(51)
US GAAP operating income (loss)	(154)	(144)	(90)	231
Financial income (expense)	(25)	(34)	(11)	(5)
Income tax benefit (expense)	(1)	(3)	(0)	(1)
US GAAP net income (loss)	(180)	(181)	(101)	224

US GAAP net loss of CHF 180 m mainly included the Non-GAAP net loss (CHF 258 m), depreciation and amortization (CHF 14 m), share-based compensation (CHF 17 m), a consent fee paid in shares to the bondholders resulting from amended terms of the 2024 convertible bonds (CHF 14 m), losses on marketable securities (CHF 2 m), a net gain from asset disposals deriving from the Viatris Deal (CHF 125 m) and restructuring charges (CHF 1 m).

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Shares

(in millions)	Issued	Potentially dilutive equity instruments		Total potential issued shares
		Derivatives	Awards	
Dec 31, 2023	188.5	54.0	14.6	257.2
Issued	0.3	27.4	6.6	34.4
Vested	0.5	-	(0.5)	-
Forfeited	-	-	(2.6)	(2.6)
Expired	-	-	(0.1)	(0.1)
Sep 30, 2024	189.3	81.5	18.1	288.9

Issued shares increased to 189.3 million mainly due to the vesting of equity awards. Issued shares include 1.0 million treasury shares held by the Group.

Equity derivatives of 81.5 million related to the Group's outstanding convertible debts of which 29.1 million related to convertible loan from J&J, 19.0 million related to the convertible bonds due in 2028 and 33.3 million related to the convertible bonds due in 2024, which increased from 5.9 million in August 2024 when the amendments to the bonds' terms became effective.

Equity awards of 18.1 million comprised of 10.5 million share options with a weighted average strike price of CHF 15.69 granted to eligible employees and 7.6 million unvested share units granted to eligible employees.

Earnings per share (EPS)

(in CHF millions, unless otherwise indicated)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Non-GAAP net income (loss)	(258)	(420)	(75)	(51)
Weighted-average number of basic shares (in millions)	180.5	178.2	182.4	178.4
Non-GAAP basic EPS (in CHF)	(1.43)	(2.36)	(0.41)	(0.29)
Weighted-average number of dilutive shares (in millions)	180.5	178.2	182.4	178.4
Non-GAAP diluted EPS (in CHF)	(1.43)	(2.36)	(0.41)	(0.29)
US GAAP net income (loss)	(180)	(181)	(101)	224
Weighted-average number of basic shares (in millions)	180.5	178.2	182.4	178.4
US GAAP basic EPS (in CHF)	(1.00)	(1.02)	(0.55)	1.26
Weighted-average number of dilutive shares (in millions)	180.5	178.2	182.4	232.5
US GAAP diluted EPS (in CHF)	(1.00)	(1.02)	(0.55)	0.96

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Cash flow and liquidity

Operating cash flow

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Operating cash flow				
US GAAP net income (loss)	(180)	(181)	(101)	224
Deferred contract revenue and accrued income	2	(6)	(1)	(1)
Deferred taxes	(0)	2	(0)	1
Intangible assets impairment charges	-	7	-	7
Depreciation and amortization	14	15	6	7
Accretion of convertible debt	1	1	0	0
Share-based compensation	17	27	6	2
Use of treasury shares	14	-	14	-
Gain on disposals of assets	(125)	(302)	-	(302)
Other non cash items	2	4	(1)	0
Net outflows from operations	(255)	(434)	(76)	(61)
Net change in receivables	3	(8)	5	4
Net change in inventories	(20)	(33)	(14)	(3)
Net change in trade and other payables	(5)	(2)	(17)	(6)
Net change in other operating assets and liabilities	(81)	(42)	(42)	(10)
Change in working capital	(104)	(85)	(68)	(15)
Operating cash flow	(359)	(518)	(144)	(76)

Net outflows from operations of CHF 255 m were mainly driven by the Non-GAAP operating loss (CHF 248 m) and Non-GAAP financial expenses (CHF 8 m).

The net cash outflows in working capital of CHF 104 m were mainly driven by inventory build up (CHF 20 m), and a decrease of accrued expenses and provisions, net of the Viatri Deal (CHF 80 m).

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Cash flow

(in CHF millions)	Nine months ended Sep 30,		Third quarter	
	2024	2023	2024	2023
Cash flow				
Operating cash flow	(359)	(518)	(144)	(76)
Acquisition/ Sale of tangible, intangible and other assets	(2)	(8)	(1)	(2)
Free cash flow	(361)	(527)	(145)	(78)
Proceeds/ (repayments) of borrowings	(0)	(0)	-	(30)
Other items	0	(3)	(1)	0
Impact from the Viatri Deal	308	319	-	319
Cash flow¹	(53)	(211)	(146)	211

¹Cash flow is reconciled with the liquidity movements shown below.

The negative cash flow of CHF 53 m was mainly driven by the operating cash outflow (CHF 359 m) and CHF 308 m from the Viatri Deal.

Liquidity

(in CHF millions)	Liquidity
Liquidity Dec 31, 2023	145
Liquidity movements Q1	190
Liquidity Mar 31, 2024	335
Liquidity movements Q2	(98)
Liquidity Jun 30, 2024	237
Liquidity movements Q3	(146)
Liquidity Sep 30, 2024	92

As of September 30, 2024, liquidity of CHF 92 m consisted of cash and cash equivalents only.

Liquidity of CHF 92 m was mainly held in Swiss francs (CHF 81 m), US dollars (equivalent of CHF 4 m) and Euro (equivalent of CHF 5 m).

Material uncertainty to continue as a going concern

The unaudited interim consolidated financial report has been prepared on the basis that the Group will continue as a going concern. This will require to secure additional funding as the liquidity (CHF 92 m as of September 30, 2024) does not cover the negative cashflow for the next twelve months based on our current business plan.

While the Group is actively seeking to raise additional cash, there can be no assurance that the necessary funding will be available.

If the Group is unable to obtain adequate resources to fund the operations, the operations will need to be further modified. If such measures are not sufficient, and/or additional funding is not obtained in due course, the Group may be forced to discontinue its operations entirely.

This material uncertainty may cast substantial doubt about the going concern of the Group. Refer to Note 1. of the unaudited interim consolidated financial report of the first half of 2024 for further details regarding the going concern assessment.

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Balance sheet

Balance sheet

(in CHF millions)	Sep 30, 2024	Jun 30, 2024	Dec 31, 2023
Assets			
Liquidity ¹	92	237	145
Tangible assets	243	249	210
Other assets	179	183	145
Total assets	513	670	500
Liabilities and equity			
Financial debt	1,294	1,294	1,293
Other liabilities	345	419	176
Total liabilities	1,639	1,713	1,469
Total equity	(1,126)	(1,043)	(969)
Total liabilities and equity	513	670	500

¹ Liquidity includes cash, cash equivalents, short- and long-term deposits

Tangible assets of CHF 243 m mainly consisted of real-estate (CHF 81 m), right-of-use assets (CHF 130 m) and other fixed assets (CHF 32 m).

Other assets of CHF 179 m comprised of prepayments (CHF 26 m), receivables (CHF 27 m), inventories (CHF 80 m), marketable securities (CHF 12 m), intangible assets (CHF 16 m), pension asset (CHF 9 m) and other assets (CHF 10 m).

Financial debt of CHF 1,294 m comprised of the convertible loan (CHF 335 m), the convertible bonds (CHF 797 m) and a sale and leaseback transaction (CHF 162 m).

Other liabilities of CHF 345 m included current and noncurrent liabilities. Current liabilities of CHF 176 m mainly comprised of accrued expenses (CHF 149 m), payables (CHF 17 m) and a short-term lease liability (CHF 9 m). Noncurrent liabilities of CHF 169 m mainly comprised of a long-term lease liability (CHF 119 m), accrued expenses (CHF 43 m) and other noncurrent liabilities (CHF 6 m).

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Reconciliation of US GAAP to non-GAAP results

Reconciliation of US GAAP to non-GAAP results for the nine months ended September 30, 2024

(in CHF millions, unless otherwise indicated)	US GAAP results	Depreciation, amortization, impairment	Share-based compensation	Other items	Non-GAAP results
Net revenue					
Product sales	49	-	-	-	49
Contract revenue – royalties	1	-	-	-	1
Contract revenue – milestones	3	-	-	-	3
Total net revenue	53	-	-	-	53
Operating expenses					
Cost of sales	(16)	-	-	-	(16)
Research and development	(111)	9	6	-	(95)
Selling, general and administrative	(206)	2	10	-	(194)
Amortization of intangible assets	(2)	2	-	-	-
Restructuring charges	(1)	-	-	1	-
Gains on sale of disposal group	125	-	-	(125)	-
Total operating expenses	(211)	14	17	(125)	(305)
Other income	5	-	-	-	5
Operating results	(154)	14	17	(125)	(248)
Total financial income (expense)	(25)	-	-	17	(8)
Income before income tax benefit (expense)	(179)	14	17	(107)	(256)
Income tax benefit (expense)	(1)	(0)	(1)	(0)	(1)
Net income (loss)	(180)	14	16	(107)	(258)
Basic net income (loss) per share (CHF)	(1.00)	0.07	0.09	(0.59)	(1.43)
Weighted-average number of basic shares (in millions)	180.5	-	-	-	180.5
Diluted net income (loss) per share (CHF)	(1.00)	0.07	0.09	(0.59)	(1.43)
Weighted-average number of dilutive shares (in millions)	180.5	-	-	-	180.5

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Reconciliation of US GAAP to non-GAAP results for the third quarter 2024

(in CHF millions, unless otherwise indicated)	US GAAP results	Depreciation, amortization, impairment	Share-based compensation	Other items	Non-GAAP results
Net revenue					
Product sales	25	-	-	-	25
Contract revenue – royalties	1	-	-	-	1
Contract revenue – milestones	1	-	-	-	1
Total net revenue	26	-	-	-	26
Operating expenses					
Cost of sales	(12)	-	-	-	(12)
Research and development	(40)	4	3	-	(34)
Selling, general and administrative	(65)	1	4	-	(60)
Amortization of intangible assets	(1)	1	-	-	-
Total operating expenses	(118)	6	6	-	(106)
Other income	2	-	-	-	2
Operating results	(90)	6	6	-	(78)
Total financial income (expense)	(11)	-	-	14	3
Income before income tax benefit (expense)	(101)	6	6	14	(75)
Income tax benefit (expense)	(0)	(0)	(0)	0	(0)
Net income (loss)	(101)	6	6	14	(75)
Basic net income (loss) per share (CHF)	(0.55)	0.03	0.03	0.08	(0.41)
Weighted-average number of basic shares (in millions)	182.4	-	-	-	182.4
Diluted net income (loss) per share (CHF)	(0.55)	0.03	0.03	0.08	(0.41)
Weighted-average number of dilutive shares (in millions)	182.4	-	-	-	182.4

The non-GAAP metrics are reported in addition to, not as a substitute for, US GAAP financial performance, as management believes that they provide useful supplementary information to investors and more accurately reflect the underlying business performance.

Contents

> Financial Review

Unaudited Interim
Consolidated
Financial Statements

Unaudited Interim Consolidated Financial Statements

Contents

Financial Review

➤ Unaudited Interim
Consolidated
Financial Statements



Interim Consolidated Income Statement

	Nine months ended September 30,	
	2024	2023
(in CHF thousands, except per share amounts)	(unaudited)	(unaudited)
Net revenue		
Product sales	48,570	53,922
Contract revenue	4,038	76,950
Total net revenue	52,608	130,872
Operating (expenses)¹		
Cost of sales	(16,032)	(6,662)
Research and development	(110,955)	(234,493)
Selling, general and administrative	(206,326)	(314,329)
Amortization of intangible assets	(2,264)	(3,831)
Impairment of intangible assets	-	(6,643)
Restructuring charges	(771)	(11,120)
Gains on sale of disposal group	125,327	301,938
Total operating (expenses)	(211,021)	(275,140)
Other income	4,655	477
Operating income (loss)	(153,759)	(143,791)
Interest income (expense), net	(13,775)	(14,927)
Accretion of convertible debt	(888)	(945)
Other financial income (expense), net	(10,760)	(18,336)
Total financial income (expense)	(25,423)	(34,208)
Income (loss) before income tax benefit (expense)	(179,182)	(177,999)
Income tax benefit (expense)	(570)	(3,246)
Net income (loss)	(179,752)	(181,245)
Basic net income (loss) per share attributable to Idorsia's shareholders	(1.00)	(1.02)
Weighted-average number of common shares (in thousands)	180,481	178,208
Diluted net income (loss) per share attributable to Idorsia's shareholders	(1.00)	(1.02)
Weighted-average number of common shares (in thousands)	180,481	178,208
¹Includes share-based compensation as follows:		
Research and development	6,394	12,143
Selling, general and administrative	10,169	14,817
Total share-based compensation	16,563	26,960

Contents

Financial Review

> **Unaudited Interim Consolidated Financial Statements**

Interim Consolidated Statement of Comprehensive Income

(in CHF thousands)	Nine months ended September 30,	
	2024	2023
	(unaudited)	(unaudited)
Net income (loss)	(179,752)	(181,245)
Other comprehensive income (loss), net of tax:		
Foreign currency translation adjustments	174	(1,512)
Change of unrecognized components of net periodic benefit costs	(1,095)	(12,437)
Other comprehensive income (loss), net of tax	(921)	(13,949)
Comprehensive income (loss)	(180,673)	(195,194)

Contents

Financial Review

> **Unaudited Interim
Consolidated
Financial Statements**

Interim Consolidated Balance Sheet (1/2)

	Sep 30,	Dec 31,
	2024	2023
	(unaudited)	(audited)
<i>(in CHF thousands, except number of shares)</i>		
ASSETS		
Current assets		
Cash and cash equivalents	91,635	145,052
Trade and other receivables, net	26,792	28,791
Receivables from related parties	584	1,145
Inventories	79,662	59,146
Marketable securities	11,515	12,764
Other current assets	25,593	29,386
Total current assets	235,781	276,284
Noncurrent assets		
Property, plant and equipment, net	112,086	136,671
Right-of-use assets	130,493	73,065
Intangible assets, net	16,127	3,527
Pension asset	8,798	3,540
Other noncurrent assets	9,550	6,909
Total noncurrent assets	277,054	223,712
TOTAL ASSETS	512,835	499,996

Contents

Financial Review

> **Unaudited Interim
Consolidated
Financial Statements**

Interim Consolidated Balance Sheet (2/2)

	Sep 30,	Dec 31,
	2024	2023
	(unaudited)	(audited)
<i>(in CHF thousands, except number of shares)</i>		
LIABILITIES		
Current liabilities		
Trade and other payables	16,672	19,910
Payables and accrued payables to related parties	748	322
Deferred revenue	1,067	2
Lease liability	8,661	6,275
Sales related liabilities	17,106	18,189
Accrued expenses	131,657	55,457
Provisions	45	1,322
Convertible bonds	200,000	199,847
Total current liabilities	375,955	301,326
Noncurrent liabilities		
Convertible loan	334,575	334,575
Convertible bonds	597,010	596,428
Other financial liabilities	162,358	162,205
Lease liability	118,784	66,501
Deferred tax liability	1,669	1,940
Other noncurrent liabilities	48,592	5,737
Total noncurrent liabilities	1,262,990	1,167,388
Total liabilities	1,638,945	1,468,713
EQUITY		
Idorsia's shareholders' equity		
Common shares (par value CHF 0.05 per share, issued and outstanding 189,306,521 and 188,480,626 as of September 30, 2024 and December 31, 2023 respectively; total number of authorized shares, including issued, conditional and upper end of capital range, 376,337,368 as of September 30, 2024 and 350,745,979 as of December 31, 2023 respectively)	9,465	9,424
Additional paid-in capital	2,178,427	2,155,617
Accumulated profit (loss)	(3,322,770)	(3,143,019)
Treasury shares	(52)	(483)
Accumulated other comprehensive income (loss)	8,821	9,742
Total Idorsia's shareholders' equity	(1,126,110)	(968,718)
TOTAL LIABILITIES AND EQUITY	512,835	499,996

Contents

Financial Review

➤ **Unaudited Interim
Consolidated
Financial Statements**

Interim Consolidated Statement of Cash Flows (1/2)

	Nine months ended September 30,	
	2024	2023
(in CHF thousands)	(unaudited)	(unaudited)
Cash flow from operating activities		
Net income (loss)	(179,752)	(181,245)
Adjustments to reconcile net income (loss) to net cash provided from operating activities:		
Depreciation and amortization	13,672	15,079
Intangible assets impairment charges	-	6,643
Share-based compensation	16,563	26,960
Accretion of convertible debt	888	945
Fair value changes on securities	1,981	4,237
Release of deferred revenue and accrued income	2,210	(5,858)
Gain on disposals of assets	(125,327)	(301,938)
Use of treasury shares	14,072	-
Deferred taxes	(71)	1,528
Changes in operating assets and liabilities:		
Trade and other receivables	2,931	(7,668)
Prepayments	(775)	11,856
Inventories	(20,251)	(33,207)
Trade and other payables	(5,134)	(1,672)
Accrued expenses	111,231	(26,232)
Provisions	(7,908)	(43,975)
Changes in other operating cash flow items	(576)	16,242
Changes in other operating cash flows as a result of asset disposal	(182,984)	-
Net cash flow provided by (used in) operating activities	(359,230)	(518,304)
Cash flow from investing activities		
Purchase of short-term deposits	-	(50,000)
Proceeds from short-term deposits	-	320,000
Purchase of property, plant and equipment	(2,258)	(5,941)
Proceeds from sale of property, plant and equipment	14,999	-
Purchase of intangible assets	(14,997)	(2,552)
Proceeds from disposals of assets	308,048	318,858
Net cash flow provided by (used in) investing activities	305,793	580,365
Cash flow from financing activities		
Issuance of new shares, net	(80)	(197)
Proceeds from borrowings, net	-	50,000
Repayments of borrowings	-	(50,000)
Proceeds from issuance of convertible loans, net	-	10,000
Repayments of convertible loans	-	(10,000)
Net cash flow provided by (used in) financing activities	(80)	(197)

Contents

Financial Review

➤ **Unaudited Interim Consolidated Financial Statements**

Interim Consolidated Statement of Cash Flows (2/2)

(in CHF thousands)	Nine months ended September 30,	
	2024	2023
	(unaudited)	(unaudited)
Net effect of exchange rates on cash and cash equivalents	101	(2,583)
Net change in cash and cash equivalents	(53,417)	59,280
Cash and cash equivalents at beginning of period	145,052	145,998
Cash and cash equivalents at end of period	91,635	205,279

Contents

Financial Review

> **Unaudited Interim
Consolidated
Financial Statements**

Interim Consolidated Statement of Changes in Equity

	Common shares		Idorsia's shareholders			Accum. other comprehensive income (loss)	Total equity
	Shares	Amount	Additional paid-in capital	Accum. profit (loss)	Treasury shares		
<small>(in CHF thousands, except number of shares)</small>							
At January 1, 2023	177,558,532	8,878	2,126,859	(2,845,098)	-	48,403	(660,958)
Comprehensive income (loss):							
Net income (loss)				(181,245)			(181,245)
Other comprehensive income (loss)						(13,949)	(13,949)
Comprehensive income (loss)							(195,194)
Share-based compensation transactions	671,176	34	20,260				20,294
Transactions in treasury shares	10,000,000	500	4,841		(483)		4,858
At September 30, 2023 (unaudited)	188,229,708	9,411	2,151,960	(3,026,343)	(483)	34,454	(831,001)
Comprehensive income (loss):							
Net income (loss)				(116,676)			(116,676)
Other comprehensive income (loss)						(24,711)	(24,711)
Comprehensive income (loss)							(141,387)
Share-based compensation transactions	250,918	13	3,657				3,670
Transactions in treasury shares							-
At December 31, 2023 (audited)	188,480,626	9,424	2,155,617	(3,143,019)	(483)	9,742	(968,718)
Comprehensive income (loss):							
Net income (loss)				(179,752)			(179,752)
Other comprehensive income (loss)						(921)	(921)
Comprehensive income (loss)							(180,673)
Share-based compensation transactions	825,895	41	7,638				7,680
Transactions in treasury shares			15,171		430		15,601
At September 30, 2024 (unaudited)	189,306,521	9,465	2,178,427	(3,322,770)	(52)	8,821	(1,126,110)

Contents

Financial Review

➤ **Unaudited Interim Consolidated Financial Statements**

Be prepared for more

**Curious to learn more?
Reach out to us.**

Investor Relations
Idorsia Pharmaceuticals Ltd
Hegenheimermattweg 91
4123 Allschwil
Switzerland

Phone +41 58 844 10 10
investor.relations@idorsia.com
© Idorsia Pharmaceuticals Ltd 2024
www.idorsia.com

All trademarks are legally protected.
Concept and design: Markenfels AG

